ALKS vs LLY · P/E 14, rev $1.56B vs P/E 39, rev $65.18B
Alkermes Plc (ALKS) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the ALKS and LLY stock pages for the full models.
Not investment advice.